Cholestasis - A Pipeline Analysis Report

Overview of the drug development for Cholestasis

Cholestasis can be defined as the reduction in the flow of bile due to the impaired secretion of bile from hepatocytes or because of an obstruction in the flow of bile through intrahepatic or extrahepatic bile ducts. The incidence of primary biliary cholangitis (PBC) is increasing as more screening tests are being performed in otherwise healthy persons. The PBC condition is quite common among the middle-aged women worldwide.  According to NIH, the age-adjusted incidence of PBC in the US per million person-years for women is 45. PBC is mostly believed to be a North American and European disease. However, the prevalence and incidence are increasingly becoming variable across different parts of the world. Based on the cholestasis market forecast, Technavio’s market research analysts predict that the rising incidences of PBC across the globe are expected to promote the drug development for Cholestasis.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of Cholestasis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Cholestasis market forecast: Companies covered

According to cholestasis industry analysis, This pipeline report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of Cholestasis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.